July 03, 2025

Is HPV-Driven SNSCC Its Own Disease?

Researchers identified key genetic differences between HPV-associated and HPV-independent sinonasal squamous cell carcinoma, revealing distinct mutations, survival risks, and potential treatment targets.

Conexiant

July 02, 2025

FDA Approves Ready-to-Infuse Vancomycin

Tyzavan is the first FDA-approved vancomycin formulation available at room temperature that requires no compounding, thawing, or dilution, enabling faster treatment in time-critical infections like sepsis.

Conexiant

June 30, 2025

ASCO 2025: Structured Exercise Program Improves Survival, Outcomes in Some Patients With Colon Cancer

A 3-year structured exercise program initiated soon after completion of adjuvant chemotherapy improves disease-free and overall survival, as well as patient-reported physical functioning and fitness, ...

The ASCO Post

June 30, 2025

Invitation to Colonoscopy vs Fecal Immunochemical Test Screening for Colorectal Cancer

Does being invited to colorectal cancer screening with fecal immunochemical tests vs colonoscopy have an impact on colorectal cancer mortality?

The ASCO Post

June 30, 2025

Incidence Rates of Colorectal and Pancreatic Cancers Are Rising Most Among Young Adults

“Clinicians should be aware of this trend in younger age groups, so their suspicion is higher when patients present with symptoms.”

The ASCO Post

June 30, 2025

DDW 2025: 20-Year Screening Program Drives Down Colorectal Cancer Cases, Deaths

A 20-year initiative that offered flexible options for colorectal cancer screening at a major integrated health system doubled colorectal cancer screening rates, cut cancer incidence by a third, halve...

The ASCO Post

June 30, 2025

Retifanlimab-dlwr Approved for Anal Cancer in Combination With Carboplatin Plus Paclitaxel and as a Single Agent

The U.S. Food and Drug Administration (FDA) approved retifanlimab-dlwr (Zynyz), a PD-1–blocking monoclonal antibody, with carboplatin and paclitaxel for the first-line treatment of adults with inopera...

The ASCO Post

June 30, 2025

Can Typos Change a Diagnosis?

Large language models used in clinical decision-making may offer different treatment recommendations depending on how a patient writes their message—even when the medical facts remain unchanged.

Conexiant

June 27, 2025

Addition of Pembrolizumab to Chemotherapy for Previously Treated Metastatic Castration-Resistant Prostate Cancer

As reported in the Journal of Clinical Oncology by Petrylak et al, the phase III KEYNOTE-921 trial showed no benefit in outcomes with the addition of pembrolizumab to docetaxel in patients with previo...

The ASCO Post